Alnylam Pharmaceuticals
Signal active
Organization
Contact Information
Overview
Alnylam is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.
About
Industries
Biotechnology, Health Care, Pharmaceutical, Medical, Therapeutics
Founded
2002
Employees
1001-5000
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Alnylam Pharmaceuticals headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical, Medical, Therapeutics sector. The company focuses on Biotechnology and has secured $621.5B in funding across 160 round(s). With a team of 1001-5000 employees, Alnylam Pharmaceuticals is actively contributing to advancements in Biotechnology. Their latest funding round, Post-IPO Equity - Alnylam Pharmaceuticals, raised $10.0M. Discover more about their projects, partnerships, and impact on our platform.
Employees
Funding Rounds
Funding rounds
8
Investors
1
Lead Investors
0
Total Funding Amount
$3884.6M
Details
1
Alnylam Pharmaceuticals has raised a total of $3884.6M in funding over 1 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2003 | Private Equity | 24.6M |
Investors
Alnylam Pharmaceuticals is funded by 13 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Cardinal Partners | - | FUNDING ROUND - Cardinal Partners | 24.6M |
| ARCH Venture Partners | - | FUNDING ROUND - ARCH Venture Partners | 24.6M |
| Alnylam Pharmaceuticals | - | FUNDING ROUND - Alnylam Pharmaceuticals | 24.6M |
| Polaris Partners | - | FUNDING ROUND - Polaris Partners | 24.6M |
Recent Activity
There is no recent news or activity for this profile.